MMedication Read More Milton Keynes GP on GLP-1 weight-loss pill UK rolloutJuly 28, 2026 Dr Adam Staten, 43, a medical director at the private diagnostics clinic hub One Day Tests, said he…
MMedication Read More Centre Approves Mounjaro, Ozempic Under CGHS, Warns Against Rule Violations | India NewsJuly 28, 2026 Last Updated:July 27, 2026, 16:50 IST CGHS have been directed to ensure strict implementation of the guidelines across…
MMedication Read More GLP-1 drugs may slow biological aging, study findsJuly 28, 2026 Weight loss drugs may slow aging process Dr. Suneil Koliwad, Chief of the Division of Endocrinology and Metabolism…
MMedication Read More Deadline fast approaching for Canadians to file claim in class-action drug suitJuly 28, 2026 The deadline is fast approaching for Canadians to claim their share of a multimillion-dollar class-action lawsuit over the…
MMedication Read More New Cholesterol Pill Lipfendra Now Approved: How It Stacks up to StatinsJuly 28, 2026 While tried-and-true high cholesterol treatments like statins are an important way to protect your heart if you have…
MMedication Read More New FDA-approved cholesterol pill lowers bad LDL | Tap to know more | Inshorts – InshortsJuly 28, 2026 New FDA-approved cholesterol pill lowers bad LDL | Tap to know more | Inshorts InshortsNewly approved pill cuts LDL…
MMedication Read More Canadians have 1 month left to file claim in class-action drug suitJuly 28, 2026 Listen to this article Estimated 1 minute The audio version of this article is generated by AI-based technology.…
MMedication Read More Weight loss drugs reduce some employee sick time, a study findsJuly 28, 2026 Savings to the overall health care economy from GLP-1 drugs have yet to be proven, but researchers have…
MMedication Read More Canada class-action lawsuit for drug Rexulti: Deadline nearsJuly 28, 2026 Updated: July 27, 2026 at 10:01AM EDT Published: July 27, 2026 at 5:32AM EDT The deadline is fast approaching for…
MMedication Read More First-in-Class Drug for ADHD Wins FDA ApprovalJuly 28, 2026 The FDA approved oral centanafadine (Simtriyo), a first-in-class triple reuptake inhibitor for attention deficit-hyperactivity disorder (ADHD), Otsuka announced…
MMedication Read More Multiple sclerosis: First drug to help patients walk now on NHS in EnglandJuly 28, 2026 Aysen Slack, 65 and from Eastbourne, chose to pay privately for the pills once she heard about them.…
MMedication Read More Africa’s most developed pharmaceutical market reviews 12 Ozempic generics as drugmakers target Novo Nordisk’s dominanceJuly 27, 2026 The applications could bring more affordable versions of one of the world’s most sought-after medicines into one…